422 related articles for article (PubMed ID: 25078054)
1. The risk of ectopic pregnancy following GnRH agonist triggering compared with hCG triggering in GnRH antagonist IVF cycles.
Sahin S; Ozay A; Ergin E; Turkgeldi L; Kürüm E; Ozornek H
Arch Gynecol Obstet; 2015 Jan; 291(1):185-91. PubMed ID: 25078054
[TBL] [Abstract][Full Text] [Related]
2. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
[TBL] [Abstract][Full Text] [Related]
3. Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles.
Humaidan P; Van Vaerenbergh I; Bourgain C; Alsbjerg B; Blockeel C; Schuit F; Van Lommel L; Devroey P; Fatemi H
Hum Reprod; 2012 Nov; 27(11):3259-72. PubMed ID: 22930004
[TBL] [Abstract][Full Text] [Related]
4. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
[TBL] [Abstract][Full Text] [Related]
5. GnRH agonist versus HCG triggering in different IVF/ICSI cycles of same patients: a retrospective study.
Yılmaz N; Ceran MU; Ugurlu EN; Gülerman HC; Engin Ustun Y
J Obstet Gynaecol; 2020 Aug; 40(6):837-842. PubMed ID: 31791167
[TBL] [Abstract][Full Text] [Related]
6. Gonadotropin Releasing Hormone Agonist Final Oocyte Maturation and Human Chorionic Gonadotropin as Exclusive Luteal Support in Normal Responders.
Beck-Fruchter R; Baram S; Geslevich Y; Weiss A
Gynecol Obstet Invest; 2019; 84(1):27-34. PubMed ID: 30048969
[TBL] [Abstract][Full Text] [Related]
7. Reproductive Outcome After GnRH Agonist Triggering With Co-Administration of 1500 IU hCG on the Day of Oocyte Retrieval in High Responders: A Long-Term Retrospective Cohort Study.
Abdulkhalikova D; Bokal EV; Stimpfel M; Ciglar P; Korosec S
Front Endocrinol (Lausanne); 2022; 13():826411. PubMed ID: 35464066
[TBL] [Abstract][Full Text] [Related]
8. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
[TBL] [Abstract][Full Text] [Related]
9. Combined administration of gonadotropin-releasing hormone agonist with human chorionic gonadotropin for final oocyte maturation in GnRH antagonist cycles for in vitro fertilization.
Kim CH; Ahn JW; You RM; Kim SH; Chae HD; Kang BM
J Reprod Med; 2014; 59(1-2):63-8. PubMed ID: 24597289
[TBL] [Abstract][Full Text] [Related]
10. Cumulative live birth rates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols.
Toftager M; Bogstad J; Løssl K; Prætorius L; Zedeler A; Bryndorf T; Nilas L; Pinborg A
Hum Reprod; 2017 Mar; 32(3):556-567. PubMed ID: 28130435
[TBL] [Abstract][Full Text] [Related]
11. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
[TBL] [Abstract][Full Text] [Related]
12. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists.
Kolibianakis EM; Schultze-Mosgau A; Schroer A; van Steirteghem A; Devroey P; Diedrich K; Griesinger G
Hum Reprod; 2005 Oct; 20(10):2887-92. PubMed ID: 15979994
[TBL] [Abstract][Full Text] [Related]
13. Dual triggering with GnRH agonist plus hCG versus triggering with hCG alone for IVF/ICSI outcome in GnRH antagonist cycles: a systematic review and meta-analysis.
Chen CH; Tzeng CR; Wang PH; Liu WM; Chang HY; Chen HH; Chen CH
Arch Gynecol Obstet; 2018 Jul; 298(1):17-26. PubMed ID: 29600322
[TBL] [Abstract][Full Text] [Related]
14. Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial.
Galindo A; Bodri D; Guillén JJ; Colodrón M; Vernaeve V; Coll O
Gynecol Endocrinol; 2009 Jan; 25(1):60-6. PubMed ID: 19165664
[TBL] [Abstract][Full Text] [Related]
15. Role of the proportion of dominant follicles in patients with polycystic ovary syndrome undergoing in vitro fertilization-embryo transfer.
Lin HY; Li Y; Wang WJ; Qiu Q; Zhang QX; Li Y
Chin Med J (Engl); 2019 Jun; 132(12):1448-1453. PubMed ID: 31205103
[TBL] [Abstract][Full Text] [Related]
16. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization.
Fauser BC; de Jong D; Olivennes F; Wramsby H; Tay C; Itskovitz-Eldor J; van Hooren HG
J Clin Endocrinol Metab; 2002 Feb; 87(2):709-15. PubMed ID: 11836309
[TBL] [Abstract][Full Text] [Related]
17. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
18. Co-administration of GnRH-agonist and hCG, for final oocyte maturation (double trigger), in patients with low proportion of mature oocytes.
Zilberberg E; Haas J; Dar S; Kedem A; Machtinger R; Orvieto R
Gynecol Endocrinol; 2015 Feb; 31(2):145-7. PubMed ID: 25385007
[TBL] [Abstract][Full Text] [Related]
19. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates.
Acevedo B; Gomez-Palomares JL; Ricciarelli E; Hernández ER
Fertil Steril; 2006 Dec; 86(6):1682-7. PubMed ID: 17074344
[TBL] [Abstract][Full Text] [Related]
20. Dual trigger with the combination of gonadotropin-releasing hormone agonist and standard dose of human chorionic gonadotropin improves
Mutlu I; Demirdag E; Cevher F; Erdem A; Erdem M
J Obstet Gynaecol; 2022 Jul; 42(5):1239-1244. PubMed ID: 34565274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]